EUVIMEDEUVIMED entdecken
Crossref

Cerebral aspergillosis under ibrutinib therapy: clinical features and management challenges

Alexandra Serris iD, François Danion, Joseph Benzakoun, Pierre Tattevin iD, Jean-Pierre Gangneux, Renaud Verdon, Julie Bonhomme, Lucie Lelièvre, Yacine Tandjaoui-Lambiotte, Thorsten Braun, Jean-Philippe Talarmin, Guillaume Desoubeaux iD und 5 weitere

Journal of Antimicrobial Chemotherapy · 04.08.2026 · 81 (9)

DOI: 10.1093/jac/dkag266 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 04.08.2026. Verfasst von Alexandra Serris und 16 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Department, Necker-Enfants Malades University Hospital, Assistance Publique-Hôpitaux de Paris, Paris Cité University, Paris, Fran…. Hauptthemen laut MEDLINE: Piperidines, Adenine, Neuroaspergillosis. Die Arbeit nennt 16 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Ibrutinib is a recognized risk factor for invasive fungal disease (IFD) recognized in the 2019 revised criteria of the European Organisation for Research and Treatment of Cancer. Cerebral aspergillosis (CA) under ibrutinib has been relatively frequently reported, but its particular characteristics remain insufficiently described.

Methods

The CEREALS study was a nationwide retrospective cohort of 119 patients diagnosed with CA between 2006 and 2018. We analysed 10 patients who developed CA following ibrutinib therapy and compared their clinical, radiological and outcome data with those of other patients with haematological malignancies from this cohort.

Results

Nine patients received ibrutinib for chronic lymphocytic leukaemia and one for diffuse large B-cell lymphoma after a median of two prior treatment lines. None received anti-mould prophylaxis, although 80% of them presented additional IFD risk factors. CA occurred a median of 2.9 months after ibrutinib initiation. All cases resulted from haematogenous dissemination, with extracerebral involvement in 70% of the patients, mostly the lungs. Brain imaging revealed supratentorial abscesses without meningeal involvement in all patients, typically manifesting with focal neurological deficits. Serum galactomannan was positive in 33% of tested patients, exclusively in neutropenic individuals. Six-week mortality was 40%. Compared with other haematological malignancy patients in the CEREALS cohort, ibrutinib-associated CA showed exclusive haematogenous spread, infrequent serum galactomannan positivity and lower mortality (40% versus 62%).

Conclusions

Cerebral aspergillosis during ibrutinib therapy shows particular features. An invasive microbiological workup is often required, as serum galactomannan appears to have limited sensitivity in this context.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PiperidinesAdenineNeuroaspergillosisHumansRetrospective StudiesFemaleMaleAgedLeukemia, Lymphocytic, Chronic, B-CellMiddle AgedGalactoseAged, 80 and overMannansLymphoma, Large B-Cell, DiffuseAntifungal AgentsRisk Factors

Substanzen

ibrutinibPiperidinesAdenineGalactoseMannansgalactomannanAntifungal Agents

Autor:innen und Institutionen

  • Infectious Diseases Department, Necker-Enfants Malades University Hospital, Assistance Publique-Hôpitaux de Paris, Paris Cité University, Paris, France.
  • Translational Immunology Unit, Institut Pasteur, Université Paris Cité, Paris, France.
  • Department of Infectious Diseases, Centre Hospitalier Universitaire de Strasbourg, Université de Strasbourg, Strasbourg, France.
  • Department of Neuroradiology, Universitéde Paris, INSERM UMR 1266, GHU Paris, Hôpital Sainte-Anne, DHU Neurovasc Paris Sorbonne, Paris, France.
  • Department of Infectious Diseases and Intensive Care Unit, Pontchaillou University Hospital, Rennes, France.
  • Department of Mycology, European Excellence Center in Medical Mycology (ECMM EC), National Reference Center for Invasive Mycoses and Antifungals- LA Asp-C, CHU Rennes, Univ Rennes, EHESP, Inserm, Irset (Institut de Rech…

ORCID-Profile: Alexandra Serris, Pierre Tattevin, Guillaume Desoubeaux

Zitieren

APA

Serris, A., Danion, F., Benzakoun, J., Tattevin, P., Gangneux, J. P., Verdon, R., Bonhomme, J., Lelièvre, L., Tandjaoui-Lambiotte, Y., Braun, T., Talarmin, J. P., Desoubeaux, G., Aguilar, C., Lortholary, O., Ghez, D., Lanternier, F., & CEREALS study group (2026). Cerebral aspergillosis under ibrutinib therapy: clinical features and management challenges. Journal of Antimicrobial Chemotherapy, 81(9). https://doi.org/10.1093/jac/dkag266

Vancouver

Serris A, Danion F, Benzakoun J, Tattevin P, Gangneux JP, Verdon R, et al. Cerebral aspergillosis under ibrutinib therapy: clinical features and management challenges. Journal of Antimicrobial Chemotherapy. 2026;81(9). doi:10.1093/jac/dkag266

BibTeX
@article{Serris2026,
  author = {Serris, Alexandra and Danion, François and Benzakoun, Joseph and Tattevin, Pierre and Gangneux, Jean-Pierre and Verdon, Renaud and Bonhomme, Julie and Lelièvre, Lucie and Tandjaoui-Lambiotte, Yacine and Braun, Thorsten and Talarmin, Jean-Philippe and Desoubeaux, Guillaume and Aguilar, Claire and Lortholary, Olivier and Ghez, David and Lanternier, Fanny and CEREALS study group, CEREALS study group},
  title = {Cerebral aspergillosis under ibrutinib therapy: clinical features and management challenges},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2026},
  volume = {81},
  number = {9},
  doi = {10.1093/jac/dkag266}
}
Kostenlos starten →